The CYP2C19*2 and CYP2C19*17 Polymorphisms Influence Responses to Clozapine for the Treatment of Schizophrenia
Received 22 August 2019
Accepted for publication 21 December 2019
Published 11 February 2020 Volume 2020:16 Pages 427—432
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Roger Pinder
Christielly Rodrigues-Silva,1 Agostinho Tavares Semedo,1 Hiasmin Franciely da Silva Neri,1 Rosana Pereira Vianello,2 Carlos Galaviz-Hernández,3 Martha Sosa-Macías,3 Rodrigo Bernini de Brito,1,4 Paulo César Ghedini1
1Department of Pharmacology, Institute of Biological Sciences, Federal University of Goiás, Goiânia, GO, Brazil; 2Empresa Brasileira de Pesquisa Agropecuária - Embrapa, Santo Antônio de Goiás, GO, Brazil; 3Instituto Politécnico Nacional, Academia de Genómica, CIIDIR-Durango, Durango, México; 4Brain Institute Medical Clinic, Bueno Medical Center Building, Goiânia, GO, Brazil
Correspondence: Paulo César Ghedini
Laboratório de Farmacologia Bioquímica e Molecular, Instituto de Ciências Biológicas, UFG, Cep 74690-900, Goiânia, GO, Brazil
Tel +55 62 3521-1725
Introduction: Clozapine (CLZ) is the gold standard drug for treatment-refractory schizophrenia (TRS). However, approximately 30% of patients partially respond to CLZ, defining this subset with super refractory schizophrenia (SRS). Alterations in enzyme activity may affect CLZ responses; the CYP3A4, CYP1A2 and CYP2C19 genes are primarily responsible for CLZ metabolism.
Objective: The aim of this study was to assess if CYP2C19 variants were associated with TRS or SRS.
Methods: CYP2C19*2 loss-of-function and CYP2C19*17 gain-of-function polymorphism genotype testing were performed in 108 individuals undergoing pharmacological treatment for TRS or SRS. DNA was extracted and polymorphisms were analyzed by polymerase chain reaction (PCR) and sequencing.
Results: CYP2C19*17 had positive correlations with SRS and lower Brief Psychiatric Rating Scale (BPRS) scores for TRS. In addition, CYP2C19*2 was associated with lower CLZ dosages for TRS.
Conclusion: These results show that CYP2C19*2 and CYP2C19*17 polymorphisms influence CLZ responses during schizophrenia treatment.
Keywords: schizophrenia, CYP2C19*2, CYP2C19*17, treatment response, clozapine
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]